Where they practice, who they consult.
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS), Tianjin
- 30+ years in plasma-cell disorders
- English, Mandarin
What they personally lead.
Training and recognition
Leads the largest single-center multiple myeloma clinical and research program in China; principal investigator on Chinese cooperative myeloma trials including studies of carfilzomib, daratumumab, and BCMA CAR-T; senior author in Blood, Leukemia, Lancet Haematology; chair-level roles in the Chinese Hematology Association myeloma committee
What to expect
A leading consultation choice for newly diagnosed multiple myeloma needing risk stratification (FISH for del(17p), t(4;14), t(14;16), 1q gain) and for relapsed myeloma seeking access to BCMA-targeted bispecifics or CAR-T trials.
Check the public record
Look up publications, citations, and academic profile on independent platforms before reaching out.
Results are automated searches and may include other individuals with similar names.
Ask the AI or request a coordinator.
The AI can compare Qiu Lugui's background to other specialists in Tianjin. A coordinator can confirm appointment availability and English-language support.
Information is provided for reference only and may not reflect current conditions. Verify directly with the hospital before making decisions.